Contract manufacturing facilities located in the US and Europe provide biopharma companies with strategic options to diversify supply chains, access specialized technologies, and speed time-to-market for new drugs. Outsourced dose manufacturing for innovator drugs and biosimilars approved in the US and Europe (the EU and UK) has traditionally oscillated between the two geographies, but there has been a pronounced shift toward European facilities over the last two years, according to GlobalData, a leading intelligence and productivity company.
According to GlobalData’s Drug By Manufacturer Database, the most recent full-year figures show a widening of the gap between the use of European and US facilities, with the first half of 2026 continuing that trend. In 2025, 50% of new drugs had dose manufacturing contracts with European-based facilities, almost doubling their share since 2023.
By contrast, that proportion for US-based facilities has remained static at 18% since 2024, leading to a substantial widening of the outsourcing gap between the two geographies. Despite fluctuations over the last decade, including instances when US-based facilities came close to European outsourcing proportions in 2018, 2021, and 2023, Europe has continuously held its lead.
Katia Djebbar, Pharma Analyst at GlobalData, comments: “National tax systems are one element supporting the growth in European contract manufacturing. Irish facilities accounted for 13% of the region’s dose manufacturing contracts in 2025, up from approximately 6% in 2024. Ireland increased its Research and Development (R&D) Corporation Tax Credit to 35% in January 2026. It is now one of the most competitive rates in Europe. Germany, which contributed just over a fifth of European dose outsourcing for new drugs in 2025, also offers a generous R&D tax credit of 25–35%. By contrast, the US offers companies an Alternative Simplified Credit of between 6% and 14% (depending on increases in R&D spending).”
Policies such as R&D tax credits are one lever for countries to encourage CDMOs to develop manufacturing techniques and technologies, and support the expansion of specialized facilities on European soil. Biosimilars, in particular, tend to require scalable commercial manufacturing and specialized production technology. Celltrion Inc., which specializes in generic and biosimilar drug development, outsourced nine dose manufacturing contracts to European facilities in 2025, up from seven in 2024, reflecting its reliance on specialized European manufacturing partners.
Djebbar continues: “Although dose outsourcing of newly approved drugs to the US and Europe has fluctuated over the past decade, the gap between the two regions was at its widest in 2025, and 2026 looks set to extend that picture of biopharma’s strategic preference for European outsourcing facilities.”
For more information
To gain access to our latest press releases: GlobalData Media Centre
Analysts available for comment. Please contact the GlobalData Press Office:
Email: pr@globaldata.com
Asia-Pacific: +91 40 6616 6809
For expert analysis on developments in your industry, please connect with us on:
GlobalData | LinkedIn | X
Notes to Editors
- Quotes provided by Katia Djebbar, Pharma Analyst at GlobalData
- This press release was written using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts
About GlobalData GlobalData Plc (LSE:DATA) operates an intelligence platform that empowers leaders to act decisively in a world of complexity and change. By uniting proprietary data, human expertise, and purpose-built AI into a single, connected platform, we help organizations see what’s coming, move faster, and lead with confidence. Our solutions are used by over 5,000 organizations across the world’s largest industries, delivering tailored intelligence that supports strategic planning, innovation, risk management, and sustainable growth.
